Evidence map›Paper›PMID 40483538›Full record

Observational studyFuture oncology (London, England)2025

J-REGISTER: real-world study of Japanese patients with

Teppei Yamaguchi, Haruko Daga, Hisashi Tanaka, Takashi Kijima, Masaya Mizushima

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04795245 (J-REGISTER), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04795245 completednot on this map

J-REGISTER: Japanese REal-world Data for Treatment of Afatinib (GIotrif®) in First-line Setting and Subsequent Therapies for Patients With Advanced EGFR Mutation-positive Lung Adenocarcinoma

TypeobservationalSponsorBoehringer IngelheimRan2021 to 2023Enrolled805ConditionsNon-squamous, Non-Small Cell Lung CancerArmsafatinib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Teppei YamaguchiDepartment of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Haruko DagaDepartment of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Hisashi TanakaDepartment of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Takashi KijimaDepartment of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Masaya MizushimaClinical Development Medical Affairs Oncology and Immunology, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe J-REGISTER study assessed outcomes and subsequent treatment in patients with PATIENTS &

methodsThis retrospective study assessed 805 patients treated with afatinib in Japan. The primary objective was time on treatment with afatinib. Other objectives included time on treatment from initiation of afatinib until the end of second-line therapy, and overall survival.

resultsMedian time on treatment with afatinib was 13.4 months (14.3/10.1 months in patients with common/uncommon mutations). Median overall time on treatment was highest in patients who received sequential afatinib and osimertinib (32.8 months). Median overall survival was 41.2 months.

conclusionAfatinib is an effective first-line treatment option for Japanese patients with CLINICAL

trial registrationNCT04795245.

Indexed as

AfatinibCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationProtein Kinase InhibitorsAcrylamidesAdultAgedAged, 80 and overAniline CompoundsEast Asian PeopleErbB ReceptorsFemaleHumansJapanMaleAcrylamidesAfatinibAniline CompoundsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsAfatinibepidermal growth factor receptorJapannon-small cell lung cancerosimertinib

Identifiers

PMID40483538
PMCPMC12218542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.